 Monoamine Oxidase Inhibitors
"Monoamine Oxidase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)
| Descriptor ID |
D008996
|
| MeSH Number(s) |
D27.505.519.389.616
|
| Concept/Terms |
Monoamine Oxidase Inhibitors- Monoamine Oxidase Inhibitors
- Inhibitors, Monoamine Oxidase
- Monoamine Oxidase Inhibitor
- Inhibitor, Monoamine Oxidase
- MAO Inhibitors
- Inhibitors, MAO
|
Below are MeSH descriptors whose meaning is more general than "Monoamine Oxidase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Monoamine Oxidase Inhibitors".
This graph shows the total number of publications written about "Monoamine Oxidase Inhibitors" by people in this website by year, and whether "Monoamine Oxidase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1987 | 0 | 2 | 2 | | 1990 | 0 | 1 | 1 | | 1991 | 1 | 0 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 2 | 1 | 3 | | 1997 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 2003 | 3 | 0 | 3 | | 2005 | 1 | 1 | 2 | | 2006 | 2 | 0 | 2 | | 2009 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Monoamine Oxidase Inhibitors" by people in Profiles.
-
Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D. Treatment of early Parkinson's disease. Part 1. Eur Neurol. 2009; 61(4):193-205.
-
Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D. Treatment of early Parkinson's disease. Part 2. Eur Neurol. 2009; 61(4):206-15.
-
Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, Oakes D, Blindauer K, Salzman P, Oren S, Prisco UL, Stern M, Shoulson I. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci. 2006 Oct 25; 248(1-2):78-83.
-
Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I. Safety of rasagiline in elderly patients with Parkinson disease. Neurology. 2006 May 09; 66(9):1427-9.
-
Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005 May; 20(5):523-39.
-
Pollack MH. The pharmacotherapy of panic disorder. J Clin Psychiatry. 2005; 66 Suppl 4:23-7.
-
Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH, Hollander E, Nutt DJ, Okasha A, Swinson RP. WCA recommendations for the long-term treatment of panic disorder. CNS Spectr. 2003 Aug; 8(8 Suppl 1):17-30.
-
Stein DJ, Bandelow B, Hollander E, Nutt DJ, Okasha A, Pollack MH, Swinson RP, Zohar J. WCA Recommendations for the long-term treatment of posttraumatic stress disorder. CNS Spectr. 2003 Aug; 8(8 Suppl 1):31-9.
-
Van Ameringen M, Allgulander C, Bandelow B, Greist JH, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP. WCA recommendations for the long-term treatment of social phobia. CNS Spectr. 2003 Aug; 8(8 Suppl 1):40-52.
-
Pollack MH. Social anxiety disorder: designing a pharmacologic treatment strategy. J Clin Psychiatry. 1999; 60 Suppl 9:20-6.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|